VIPS - Vaccine Innovation Prioritisation Strategy
(focusing on vaccine product attributes)
June 2018, Geneva
VIPS: Vision and goal

**VISION**

- **Innovation** is one of the **Alliance priorities** for shaping markets to the benefit of Gavi-supported countries.
- In this strategic period, the Alliance aims to pursue a common agenda of **driving vaccine product innovation to better meet country needs** and support Alliance goals on immunisation coverage and equity.

**GOAL**

- Prioritise innovations in vaccine product attributes to provide **greater clarity to manufacturers and partners** to make investment decisions.
The Innovation mandate is described in the Gavi’s Supply and Procurement Strategy 2016-2020

Understand countries’ needs by leveraging countries’ and technical partners’ field experience to consider financial and non-financial impact of innovations (e.g. safety, efficacy, equity & coverage)

Develop common principles across the Alliance to make the assumptions underpinning the value proposition for innovations explicit and weighing the benefits of long-term product innovations

Convene a platform to articulate a clear and aligned perspective on what to prioritise in long-term innovation, and communicate these priorities to provide greater clarity for manufacturers or partners to make investment decisions
VIPS is a close Alliance-wide collaboration effort
Landscape of vaccine product attribute innovations in scope of VIPS

Scope of innovations: antigen-agnostic or antigen-specific

**Primary containers**
- i.e. Compact pre-filled autodisable device (cPAD);
- Blow-fill-seal (BFS) container;
- Dual-chamber technology;
- Microarray patch (MAP);
- Optimised doses per container;
- Multi-mono-dose; Pre-filled syringe; Cartridge based injection

**Formulation**
- i.e. Heat-stable formulations;
- Freeze-stable formulations

**Packaging**
- i.e. Bundling accessories; Packed volume

**Labelling**
- i.e. barcode including global trade item number (GTIN);
- temperature indicators

**Delivery technologies**
- i.e. Autodisable syringe; Reuse prevention (RUP) syringe;
- Safety syringe; Sharps injury protection (SIP) syringe;
- Biodegradable implant injector (w/ biodegradable implant formulation);
- Disposable-syringe jet injector;
- Dry powder inhaler; Nebuliser; Liquid intranasal spray or drop device;
- Needle-based intradermal delivery device;
- Electroporation device;
- Fast-dissolving tablets;
- Sublingual films; Thermo-responsive gels; Intradermal adapter

**VIPS**
- Vaccine Innovation Prioritisation Strategy
VIPS evaluation framework will prioritise first antigen-agnostic innovations, then antigen-specific innovations.

**Preparatory phase**
- **Analyses**
  - Long lists of Innovations and Country needs.

**Phase 1**
- Development of methodology and analytical framework with evaluation criteria (+/- TSE).
- Data gathering & application of analytical framework.
- Short list of AA* innovations.

**Phase 2**
- In-depth analyses (TSE).
- Final AS** prioritisation decisions.

**Antigen-agnostic (AA) innovations**
- Consultations, (w/ countries and technical partners).
  - Input into development of evaluation criteria.
  - Validate conclusions and needs.

**Antigen-specific (AS) innovations**
- Validate conclusions and analyses and identify additional considerations.
VIPS governance will rely on an Alliance Working Group and a Steering Committee (SC)

**Preparatory phase**

- **Project Management**
  - **Alliance Working Group (Gavi, WHO, BMGF, UNICEF, PATH)**
  
  **Analyses**
  - Landscaping of:
    - Innovations (current, planned, desired)
    - Country needs
  - Long lists of Innovations and Country needs
  
  **Development of methodology and analytical framework with evaluation criteria (+ / - TSE)**

**Phase 1**

- **SC**
  
  **Data gathering & application of analytical framework**
  
  **Short list of ‘antigen-agnostic’ innovations**

**Phase 2**

- **SC**
  
  **In-depth analyses (TSE)**
  
  **Final ‘antigen-specific’ prioritisation decisions**

**Antigen-agnostic innovations**

- Input into development of evaluation criteria
  
  **Consultations (w/ countries and technical partners)**

- Validate conclusions and needs

**Antigen-specific innovations**

- Validate conclusions and analyses and identify additional considerations

* Steering Committee
More than half of the VIPS SC members will be members from PDVAC and IPAC

VIPS SC linkages to IPAC and PDVAC and flow of communications following each SC meeting

VIPS Steering Committee (8/15 PDVAC and IPAC members)
- Reviews VIPS analysis
- Makes recommendations to VIPS Alliance WG

PDVAC
- Designated VIPS SC members from PDVAC & IPAC share VIPS SC recommendations with full IPAC and PDVAC, respectively
- Consolidated comments validated by IVB Director and shared with Alliance WG

IPAC

VIPS Alliance Working Group
- Makes a decision based on recommendations from VIPS SC, IPAC and PDVAC and communicates decision to the three committees

Legend
- Decision-making body
- Advisory body
- Formal transmission of information
- For information

VIPS SC meeting
VIPS Alliance WG TC/in-person meeting
VIPS will take place over the course of 2018-2019

<table>
<thead>
<tr>
<th>2018</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jun</td>
<td>Jan</td>
</tr>
<tr>
<td>Jul</td>
<td>Feb</td>
</tr>
<tr>
<td>Aug</td>
<td>Mar</td>
</tr>
<tr>
<td>Sep</td>
<td>Apr</td>
</tr>
<tr>
<td>Oct</td>
<td>May</td>
</tr>
<tr>
<td>Nov</td>
<td>Jun</td>
</tr>
<tr>
<td>Dec</td>
<td>Jul</td>
</tr>
</tbody>
</table>

**Phase 1: Antigen-agnostic (AA) innovations**
- 1st Steering Committee Meeting
- Analyses of 4-5 AA innovations
- Analyses of all AA innovations
- Online survey
- F2F interviews (HCW)

**Phase 2: Antigen-specific (AS) innovations**
- 2nd Steering Committee Meeting
- AS analyses of shortlisted innovations
- F2F interviews
- Interviews with technical experts and partners

**Project Management**
- Alliance Working Group

**Analyses**
- Development of framework
- Analyses of all AA innovations

**Country Consultations**
- Online survey
- F2F interviews (HCW)

**Technical Consultations**
- Interviews with technical experts and partners

**Other Key Engagements**
- PDVAC, IPAC, DCVMN, IFPMA
- SAGE, DCVMN, IFPMA

**Key Deliverables**
- Short-list of antigen-agnostic innovations
- Final prioritisation decisions of antigen-specific innovations
As a summary

VIPS is an Alliance wide effort to drive product innovation to better meet country needs and support Alliance goals on immunisation coverage and equity

- ‘VIS*-like’ framework, leveraging TSE and existing capabilities
- Focusing on innovations in vaccine product attributes
- 2018-2019

Outcomes: An Alliance common voice

- Through a clear and aligned perspective on prioritisation of vaccine innovations
- To provide greater clarity to manufacturers and partners to make investment decisions.

* Gavi’s Vaccine Investment Strategy
Thank you